Transcatheter tricuspid valve-in-valve implantation with bioprosthetic balloon expandable valve

Haji-Zeinali, Ali-Mohammad; Etesamifard, Nasrin; Mohammadi, Zohre; Haji-Zeinali, Mohammad-Mohsen; Sahebjam, Mohammad; Abbasi, Kiomars

doi:10.1007/s11748-022-01829-z

Cited by 3 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of these cases were ideal; both patients had good hemodynamics and symptom improvement. Although the transvalvular gradient in 1-year follow-up slightly increased, it was a common phenomenon after transcatheter ViV treatment ( 19 ), and this phenomenon might relate to many factors, such as heart remodeling, without postoperative guideline-directed medical treatment (GDMT), poor preoperative heart function, and so on. Referring to the tricuspid valve with normal physiology, the average gradient is generally less than 5 mmHg ( 20 ).…”

Section: International Multidisciplinary Team (Imdt) Discussionmentioning

confidence: 99%

Transcatheter valve-in-valve implantation treatment with the J-valve system for tricuspid bioprosthesis deterioration: a report of two cases

Wu,

Shen,

Meng

et al. 2024

J Thorac Dis

View full text Add to dashboard Cite

Background Patients with tricuspid bioprosthetic structural valve degeneration (SVD) often present with right ventricular enlargement and severe dysfunction, which cause a higher risk for redo cardiac surgery. In 2019, our center innovated using the J-valve system for valve-in-valve (ViV) implantation to treat tricuspid bioprosthetic SVD. The purpose of this study was to summarize the clinical effect after 1-year follow-up. Case Description From April 2019 to October 2019, two cases of tricuspid bioprosthetic dysfunction were treated with the J-valve system. Both patients were male, aged 46 and 67 years, respectively. The preoperative evaluation showed that the risk of conventional redo open heart surgery was high. The J-valve implantation was successful in both cases. One patient had slight valve displacement when the transporter was withdrawn during the operation, and a second J-valve was implanted in an ideal position. There was no death, no delayed valve displacement, and no readmission during the follow-up period of 12 months. In both cases, there was an absence of trace tricuspid regurgitation. After 6 months of anticoagulation with warfarin, the patients were converted to long-term aspirin treatment. Conclusions The ViV technique with J-valve is feasible and effective in treating tricuspid bioprosthetic SVD in high-risk patients, avoiding cardiopulmonary bypass and conventional thoracotomy injury.

show abstract

Section: International Multidisciplinary Team (Imdt) Discussionmentioning

confidence: 99%

Transcatheter valve-in-valve implantation treatment with the J-valve system for tricuspid bioprosthesis deterioration: a report of two cases

Wu,

Shen,

Meng

et al. 2024

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…17,18 Valve-in-valve implantation is a promising alternative for failing tricuspid bioprosthesis, which provides ideal landing zone for percutaneous valve insertion via different venous routes. 17 Despite success, complications like embolization, leakage, access issues, and thrombosis exists. 18 Precise fluoroscopy and TOE guidance, along with MSCT planning, are crucial.…”

Section: Discussionmentioning

confidence: 99%

“…18 TVIV demonstrates safety and feasibility, providing a viable alternative for high-surgical-risk patients with degenerated bioprosthesis. 1,17 Adequate planning and periprocedural antithrombotic therapy play a crucial role in guaranteeing a successful outcome, offering a reliable alternative for high-risk patients. Strategies for success include preprocedural study of the existing prosthesis, close examination of the aorto-mitral area, aortic valve, the mitral prosthesis, and the distance between them.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Tricuspid valve replacement favors bioprosthetic over mechanical valves due to reduced thrombosis and bleeding risks 17 . However, bioprosthesis degenerate over time, necessitating reintervention 17,18 . Valve‐in‐valve implantation is a promising alternative for failing tricuspid bioprosthesis, which provides ideal landing zone for percutaneous valve insertion via different venous routes 17 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Combined transcatheter aortic valve and tricuspid valve‐in‐valve implantation in a patient with a mitral mechanical prosthesis

Lima,

Brito,

Almeida

et al. 2024

Cathet Cardio Intervent

View full text Add to dashboard Cite

Despite progressively uncommon in Western countries, rheumatic heart disease still portrays a significant global burden. In elderly or high‐surgical risk patients, plurivalvular disease may require a complex percutaneous approach. Transcatheter aortic valve implantation (TAVI) in patients with previous monoleaflet mitral prosthesis is challenging due to interference between the aortic valve and the rigid mitral mechanical prosthesis “ring.” Prior cases report the use of CoreValve or Edwards Sapien aortic valves in patients with adequate mitro‐aortic distance. Performing a second major procedure, such as tricuspid valve‐in‐valve (TVIV), sequentially during a single percutaneous intervention, increases treatment complexity. An 83‐year‐old woman with rheumatic heart disease, with previous implantation of a Bjork–Shiley monoleaflet mitral prosthesis, and Carpentier‐Edwards 29 tricuspid bioprosthesis presented with decompensated heart failure due to severe aortic stenosis and tricuspid bioprosthesis stenosis. After HeartTeam discussion, the patient was deemed as inoperable due to a prohibitive surgical risk. As an alternative, a TAVI (Navitor FlexNav) and a transcatheter TVIV replacement (Edwards Sapiens 3 Ultra) were discussed and proposed, with both techniques being performed sequentially in a single procedure. TAVI in a patient with a previous monoleaflet mitral mechanical prosthesis and TVIV may be a feasible approach in inoperable patients with plurivalvular disease.

show abstract

Transcatheter Tricuspid Valve Replacement: Case Selection, Technical Considerations, and Procedural Planning

Shabbir,

Yadav,

Tiwari

et al. 2023

US Cardiol

View full text Add to dashboard Cite

Tricuspid regurgitation (TR) is a highly prevalent valve disorder in the US, with prevalence increasing with age. Without treatment, severe TR carries a poor prognosis. Tricuspid valve (TV) surgery is recommended for patients with severe TR undergoing left-sided valve surgery. Transcatheter TV repair or transcatheter TV replacement are potential options for patients who are not surgical candidates. A few small studies have demonstrated the feasibility and efficacy of transcatheter TV repair in patients with severe symptomatic TR. Careful patient selection by assessing tricuspid valve anatomy, right ventricular and pulmonary hemodynamics, candidacy for anticoagulation, comorbid conditions, and frailty is key to procedural success. Transcatheter TV repair can be performed via the transjugular or transfemoral access, and requires a large-caliber sheath (up to 45 Fr) and delivery system, particularly with dilated tricuspid annulus due to right ventricular enlargement. Multimodality imaging is essential for diagnosing TR severity, defining valve anatomy, and comprehensive functional assessment of the tricuspid valve, right atrium, and right ventricle. Several prosthetic valves, including the EVOQUE system, NaviGate system, Intrepid valve, and Cardiovalve, are currently being investigated in clinical trials.

show abstract

Transcatheter tricuspid valve-in-valve implantation with bioprosthetic balloon expandable valve

Cited by 3 publications

References 15 publications

Transcatheter valve-in-valve implantation treatment with the J-valve system for tricuspid bioprosthesis deterioration: a report of two cases

Transcatheter valve-in-valve implantation treatment with the J-valve system for tricuspid bioprosthesis deterioration: a report of two cases

Combined transcatheter aortic valve and tricuspid valve‐in‐valve implantation in a patient with a mitral mechanical prosthesis

Transcatheter Tricuspid Valve Replacement: Case Selection, Technical Considerations, and Procedural Planning

Contact Info

Product

Resources

About